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In a recent paper Tillett and Francis (1) reported the finding of defi- 
nite and characteristic cutaneous reactions to certain purified chemical 
fractions of the pneumococcus in patients recovering from lobar pneu- 
monia.  In the cases studied, they showed that the type-specific poly- 
saccharide (the soluble specific substance, or "S.S.S.") injected intra- 
cutaneously at  the  time  of crisis  or  later  produces  a  "wheal and 
erythema" type of response which is specific for the type of pneumococ- 
cus causing the disease and that fatal cases fail to give such responses. 
The acetic acid precipitable fraction of the pneumococcus,  the so called 
nucleoprotein, when injected at about the time of crisis or later elicits 
a delayed tuberculin type of reaction in all cases of pneumonia without 
respect  to  the  type  of  pneumococcus  causing  the  disease.  They 
showed that these cutaneous reactions are associated with the presence 
of agglutinins and precipitins in the serum of the patient. 
These findings suggested that the type-specific skin reactions to the 
pneumococcus polysaccharides might be useful in prognosis.  Further- 
more, Tillett and Francis suggested that "persistence of infection even 
though  specific  antibodies  are  present,  may inhibit  the  skin  re- 
sponse," intimating that such reactions might be used as a simple test 
for complete recovery from the specific infection. 
This  paper  is  concerned  with:  (1)  The  cutaneous  responses  to 
* This study was aided in  part  by grants from  the William W. Wellington 
Fund of the Harvard Medical School and from the Influenza Commission of the 
Metropolitan Life Insurance Company. 
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repeated skin tests with the specific carbohydrates  of Types  I, II and 
III  pneumococci  and  circulating  specific antibodies at  various  inter- 
vals in 41  cases of lobar pneumonia  that received no  specific therapy. 
(2)  Similar studies on a  single occasion early or late  in  convalescence 
in  44  comparable  cases  and  in  24  individuals without  recent  pneu- 
monia. 
Material and Methods 
Repeated tests were done in 41 patients admitted to the medical wards of the 
Boston City Hospital during the winter and spring of 1930.  These patients all 
had  typical lobar pneumonia, clinically and radiographically.  A  pneumococcus 
of either Type I, Type II or Type III was obtained in each case from the sputum or 
the blood culture, or both.  No specific antipneumococcic agents were used in the 
treatment of these cases.  There were 30 recovered and 11 fatal cases.  15 of the 
.the former had Type I, 7 had Type II and 8 had Type III infection; of the 11 fatal 
cases, 5 were caused by Type I, 4 by Type II and 2 by Type III pneumococci.  A 
positive blood culture was obtained in only 2 of the recovered cases (J. S., Type I, 
and J. K., Type II (Fig. 1) ; whereas, 9  of the fatal cases had a  pneumococcemia. 
The presence of complications will be mentioned later.  The patients ranged in 
age from 13 to 58 years.  Only 5 of the patients were females. 
Skin tests were done on a single occasion 4 to 23 days after crisis in 35  cases of 
lobar pneumonia that received no specific antipneumococcic therapy, but were,  in 
all respects, similar to  the cases mentioned above.  The sera of many of these 
cases were tested for antibodies during the acute disease and at the time of crisis, 
as well as at  the  time  that  the skin tests were performed.  9  other cases were 
studied on one occasion 5 to 14 months after recovery from pneumonia not specif- 
icaUy treated.  24  hospital patients with  no  recent  history of pneumonia were 
studied.  These included cases of peptic ulcer,  chronic arthritis and blood and 
cardiac diseases.  The ages of the latter group ranged from 13 to 77 years. 
Skin Tests.--A 1:200 solution of each of the Types I, II and III purified specific 
carbohydrates was  obtained from  the Hospital of The Rockefeller Institute for 
Medical Research, through the courtesy of Dr. W. S. Tillett.  1 : 10,000 dilutions 
were prepared every few days from the stock solutions by diluting with physio- 
logical saline freshly made with redistilled water and then heating for 10 minutes 
at 100°C.  to insure sterility.  0.1  cc. of each of these 3 solutions (containing 0.01 
rag. of the carbohydrate) and of a control of the saline used in making the dilutions 
were injected intradermally on the flexor surface of the forearm.  All 4 injections 
were repeated at various intervals during the acute disease and during convales- 
cence.  In a few instances where positive tests were obtained, higher dilutions up 
to t :30,000,000 were used in order to determine the smallest amount with which a 
positive test could be obtained. 
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shortly before, occasionally after, almost every test.  The titer of agglutinins and 
of mouse protective antibodies for Types I, II and III pneumococci was determined 
in most instances.  Agglutination tests  were done by the method employed by 
Tillett and Francis (1).  Protective antibodies were determined bythe usualmouse 
method.  Precipitin tests were done with the specific carbohydrates and with  cul- 
ture filtrates, but the results were irregular and are not reported. 
Varieties  of Cutaneous  Reactions  to  the  Specific  Polysaccharides.--The  intra- 
cutaneous injection of the type-specific carbohydrates usually produces no greater 
response than does the injection of an equal amount of physiological saline.  The 
response occurring in reacting individuals recovering from  lobar pneumonia has 
been described and illustrated by Tillett and Francis (1).  Fairly wide variations 
in the appearance of the reaction were  observed, in the course of this study, in 
different patients and at different times in the same patient.  These  variations 
were probably only differences in intensity, since mild reactions could be produced 
in patients who showed strong reactions to standard dosages by the injection of 
0.0001  mg.  The milder reactions consisted of a faint pink wheal, 6 to 10 mm. in 
diameter, which shaded into an area of faint erythema, 12 to 20 ram. in diameter. 
This type of reaction usually reached its maximum within 30 minutes and faded 
entirely before the end of 45 to 60 minutes.  The intense reaction consisted of an 
almost white, edematous, sharply demarcated wheal irregular in outline giving the 
appearance of "pseudopods."  1 or 2 drops of serum occasionally oozed from the 
puncture wound of this type of case.  This type of wheal was usually surrounded 
by an intense erythema, 4 to 6 era. in diameter, the periphery of which faded into 
an area of faint mottling.  Such striking reactions developed in 10 to 20 minutes 
and remained at their maximum intensity for 30 to 60 minutes, after which the 
wheal  gradually blended  with  the  surrounded  erythema  to form a  fairly  soft, 
usually non-tender,  uniform swelling lasting 6  to 48 hours.  The skin over the 
central  portion  of the  swelling usually  remained  reddened.  In rare  instances 
ecchymosis apeared in the edematous area.  Occasionally, although  no reactions 
occurred on the day of the injection, erythema was observed 24 to 72 hours later 
at the site of injection of the carbohydrate which corresponded to the type of the 
infecting pneumococcus.  Another test, performed upon noticing such a  delayed 
reaction, elicited a typical immediate reaction with the same material. 
Reactions were called doubtful when they were greater than  that produced by 
the saline control but showed a wheal less than 0.8 can. and a surrounding erythema 
less than 1.5 era. in diameter. 
Occurrence  of  Cutaneous  Reactions  to  the  Specific  Polysaccharides 
The  results  of  all  of  the  skin  tests  in  the  30  recovered  cases  are 
charted  in  Fig.  1.  Positive  cutaneous  reactions  to  the  homologous 
type polysaccharides (derived from the same type as the pneumococcus 
causing the disease) were obtained in 17 of the 30 recovered cases.  In 640  REACTIONS  AND  ANTIBODIES  IN PNELr~ONIA.  I 
addition, 10 of the 17 patients who gave homologous positive tests also 
showed positive reactions to heterologous polysaccharides.  In 2 other 
cases heterologous positive  tests were observed but  the  homologous 
carbohydrates gave negative reactions.  All the heterologous positive 
responses in cases due to Types I  and III pneumococci were elicited 
with the Type II S.S.S. whereas the heterologous reactions in the Type 
FIG. 1.  Results of repeated skin tests with the specific carbohydrates of Types 
I, II and III pneumococci in 30 recovered cases of lobar pneumonia that received 
no specific  therapy. 
II cases occurred with the Type I polysaccharide.  The type distribu- 
tion of the cases and of the skin responses is summarized in Table I. 
There were 3 cases among the 30 that recovered who had purulent 
pneumococcic complications at the time of the first test.  One of these 
3 patients, a case with Type I pneumococcus empyema, gave positive 
tests with  the homologous S.S.S.  In  the other 2  cases,  one having 
purulent  Type  I  pneumococcus  arthritis  and  the  other  having  an 
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pneumococci were obtained,  the  reactions  to  all  the carbohydrates 
were negative.  There were also 2 cases that had sterile pleural effu- 
sions during convalescence.  One of these cases, a patient with Type I 
pneumonia, gave negative reactions to all tests, whereas the other, a 
Type III  case, gave positive tests with both the Type III  and the 
Type II S.S.S. 
Of the 11 fatal cases, only one showed a positive homologous test. 
In this patient characteristic positive tests were elicited 36 hours and 
12 hours before death.  Cultures taken at these times showed, respec- 
tively, 500 and 700 colonies of Type II pneumococci per cubic centi- 
meter of blood.  Heterologous positive tests were not obtained in any 
of the fatal cases. 
Occurrence of Protective Antibodies  and Agglutinins 
Protection  of  mice  against  the  homologous  type  organism  was 
demonstrated against 100 lethal doses or more in the sera of all of the 
24 recovered cases in whom tests were done on more than one occasion. 
Homologous agglutinins were present after recovery in all but 2 of the 
27 cases tested in dilutions of serum up to 1:64.  The 2 patients who 
had no agglutinins also had negative skin tests with the homologous 
polysaccharides  (C.  B.,  Type  I,  and  J.  F.,  Type In).  Protective 
antibodies for heterologous types of pneumococci  were demonstrated in 
19 of the 25 recovered cases in which such tests were carried out.  In 
3 additional cases, protection against 10 lethal doses or irregular pro- 
tection was found.  Heterologous agglutinins were present in the sera 
of 17  of the 28 patients  tested after crisis.  The findings in the re- 
covered cases are summarized by types in Table I. 
All 3 of the recovered cases having purulent complications and both 
patients with sterile pleural effusions had protection for the homologous 
and heterologous type pneumococci after the presence of the complica- 
tion was established.  Agglutinins were demonstrable in fhe sera of all 
of these patients for the homologous type organism and in one of the 
latter patients for an heterologous type. 
Among the fatal cases, homologous agglutinins were demonstrated 
only once.  This was on the day of death in a Type I patient who had 
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infected pleural fluid (reported by Lord and Persons (2)).  Protective 
antibodies for the same type were present in this case at the same time 
and also on 2 other occasions during the previous week.  No autopsy 
was obtained  on  this patient.  Homologous protection  against  more 
TABLE  I 
Summary of the Cutaneous Reactions, Agglutinins and Protective Antibodies in 30 
Recovered Cases Repeatedly Tested 
Type I tests  Type n  tests  Type nl tests 
Infecting type 
No. of cases  Cases  with  No. of cases  Cases  with  No. of cases  Cases  with 
tested  positive  tests  tested  positive  tests  tested  positive  tests 
Cutaneous reactions 
I  15  7  15  5*  15  0 
II  7  2  7  4  7  0 
III  8  0  8  0  8  6 
Agglutinins 
I  14  13"*  14  9  14  1 
II  7  1  7  7  7  2 
III  7  0  7  4  7  6 
Protective antibodies 
I  14  14  14  113:~  10  33 
II  6  3  6  6  4  2 
III  5  31  5  5  4  4 
* 2 of these failed to show  homologous positive tests,  all other cases  having 
positive tests with an heterologous S.S.S. had positive homologous tests as well. 
** 2 had agglutinins only in 1 : 2 dilution of serum. 
:~ Raised  numerals  indicate  cases  having  protection  for  10  lethal  doses  or 
irregular survivals among the mice in the higher dilutions. 
than  10  lethal  doses was not  found  in  any of  the  other  fatal  cases. 
Heterologous antibodies were never demonstrated. 
Relation of the Cutaneous Reactions and of Antibodies to the Course of the 
Disease 
Appearance of the Cutaneous Reaction to Specific Polysaccharides.--A 
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the day of crisis.  I  In 2 of these cases, the reaction was obtained on the 
day before crisis,  and,  in the 3rd, it was elicited 2  days before the 
crisis.  By the day of crisis, 11 of 25 patients tested showed positive 
reactions to the homologous S.S.S.  Whereas 12 of 25 patients tested 
by the end of the first week after crisis had already shown homologous 
positive tests, only 1 (J. McB., Type I) had a  positive test with an 
heterologous S.S.S.  within this period.  Thi's patient's  heterologous 
positive reaction was observed when he was first tested 3 days before 
crisis.  In  general, the positive tests with the homologous polysac- 
charides were first demonstrable at about the time of  crisis and, in 
some cases, while the temperature was still elevated and the patients 
appeared acutely ill.  On the other hand, heterologous positive tests 
were first elicited 8 or more days later, and often quite late in convales- 
cence.  In  particular, 3  patients  first showed heterologous positive 
responses 2, 3 and 4 months after crisis at a time when the tests with 
the homologous carbohydrates were already negative in each instance. 
Duration of the Skin Reactivity to Specific Polysaccharides.--The last 
positive test with the homologous polysaccharide was elicited less than 
1 month after crisis in 15 of the 17 cases in which homologous reactions 
occurred  (Fig.  1).  Subsequent  negative tests  with  the same types 
occurred in 9 of these 15 cases.  Positive homologous tests were eli- 
cited in only 2 of the 8 patients tested after 3 months of convalescence. 
Reactions  to  heterologous polysaccharides, on  the other hand, per- 
sisted in all but 1 of the 10 patients as long as observations continued; 
in 5 cases more than 3 months and in a 6th case 51 days after crisis. 
The duration of the skin reactivity varied with the type of poly- 
saccharide injected.  Type II reactivity was more lasting than that 
elicited by the Type I  and III carbohydrates.  It will be seen that 6 
of the 9 patients having positive reactions to the Type I polysaccharide 
gave negative responses subsequently and 2 of the remaining 3 were 
last tested only 22 days after crisis.  Only 1 case (S.R., Type II) gave 
a  positive  reaction  with  Type  I  S.S.S.  later  than  2  months  after 
recovery.  Likewise, of the 6 cases reacting to Type III polysaccharide, 
only 3 were positive at the last test which, in 2 cases, was done less than 
i In cases recovering by "lysis"  it was found that the first day of the lysis 
period corresponded with respect to circulating antibodies to the day of "crisis," 
and it is so considered  in the text and the accompanying  figures. 644  REACTIONS  AND  ANTIBODIES  IN  PNEUMONIA.  I 
2 weeks post-critically.  In contrast to these results, only 1 of the 12 
patients  having  Type II positive  reactions  failed  to give a  positive 
response at the time of the last observation.  This suggests that the 
longer duration is not a characteristic of heterologous responses as such 
but, rather, a characteristic of the reactions to the Type II S.S.S. used. 
Comparison of the Cutaneous Reactions and the Circulating Antibodies, 
and  the Rdation  of Both  to  the Course of the Disease.--The  time  of 
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appearance of the skin reaction, of agglutinins and of protective anti- 
bodies for the homologous type could be compared in 24 cases.  All 3 
immune reactions were first demonstrated simultaneously in 5  cases; 
in 12 others, the protective antibodies and agglutinins appeared at the 
same time and before the skin reaction, when that was positive; and, in 
the remaining  7 cases, protective antibodies were demonstrated before 
either of the other reactions.  Similarly,  19 cases could be compared MAXWELL FINLAND  AND  W.  D.  SUTLII~F  645 
with respect to heterologous types.  The skin reactions and the circu- 
lating antibodies were demonstrated simultaneously in 3 cases; protec- 
tive antibodies and agglutinins were found at the same time and before 
the skin  reaction in  6  cases;  and,  in  9  cases,  protective antibodies 
appeared before either of the other reactions.  In  1 case  (J. McB., 
Type I), the appearance of the positive heterologous skin reaction pre- 
ceded the finding of circulating antibodies.  The frequency with which 
antibodies were found and positive skin reactions occurred at various 
intervals is represented graphically in Fig. 2. 
When antibodies were present in any of the patients in this series they 
were demonstrated, in practically every instance, by the mouse protec- 
tion test.  The corresponding agglutinins were usually demonstrable, 
but this was not true in every case and often did not correspond at 
different times in the same case.  All cases having positive cutaneous 
reactions with the type-specific polysaccharides had protective anti- 
bodies for the corresponding type of pneumococcus at the same time, 
but agglutinins were less regularly found.  Figs. 3 to 6 show the results 
of  skin  tests  and  antibody  determinations  in  4  typical  recovered 
patients. 
From Fig. 2 it will be seen that agglutinins and protective antibodies, 
particularly the latter, appeared earlier than did the cutaneous reac- 
tion to the corresponding S.S.S., whether of the homologous or of the 
heterologous type.  The persistence of heterologous antibodies over a 
period of over 3 months is again brought out rather strikingly3  The 
homoIogous agglutinins and protective antibodies persisted longer and 
in a larger percentage of cases than did the positive skin reactions with 
the corresponding polysaccharide. 
Cutaneous  Reactions  and  Circulating  Specific  Antibodies  in  Patients 
Tested on One Occasion 
The results of the tests in patients tested once  in convalescence  and in 
those with no recent history of pneumonia are shown in Table II.  It 
is  seen that  early in  convalescence the cases which had previously 
received no skin tests frequently showed cutaneous reactions and anti- 
*  Two of the patients (S. R. and G. C. (Figs. 4 and 5)) were studied 12 and 13 
months respectively after recovery.  Cutaneous reactions and antibodies for more 
than I type were demonstrated in both of these patients. oar  or 
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bodies specific for the infecting type of pneumococcus.  A few patients 
showed heterologous skin responses and antibodies, but these were no 
more frequent than in the group of cases with no recent pneumonia. 
In the few instances where heterologous circulating antibodies were 
found at the time of the skin test, these were also shown to have been 
present during the disease.  In the cases tested 5 to 14 months after 
TABLE  II 
Summary of the Cutaneous Reactions,  Agglutinins  and  Protective Antibodies  in 3 
Groups of Cases Not Previously Tested Intradermalty 
Group I 
Tested  4  to  23  days 
after crisis 
Group II 
Tested 5 to  14 months 
after crisis 
Group III 
eases  without  recent 
pneumonia 
Type of infection 
I 
II 
III 
Miscellaneous 
pneumococci 
I 
II 
III 
No. of 
cstses 
13 
12 
4 
6 
5 
2 
2 
24** 
Positive 
cutaneous 
reactions 
Agglutinins  Protective  antibodies  present  present 
9  2  10"1011 
1  0  218  3 
0  2  0]0  2 
1  0  1  110 
r  0  0  i[oLi 
0  0  01111 
o  o  01110 
o  o  olsll 
* 2 additional cases had 10 M.L.D. and irregular survivals to 100 M'.L.D. 
** Protection tests done in 12 cases, 6 of which  had positive skin tests. 
:~ All of the cases having positive Type I tests also appear here. 
recovery, typical positive cutaneous responses were often not associated 
with corresponding agglutinins or protective antibodies.  This is in 
sharp  contrast to  the regular association of positive  skin tests with 
corresponding antibodies in patients receiving repeated injections of 
S.S.S.  The frequency of positive reactions in patients without recent 
pneumonia is also in sharp contrast to the almost complete absence of 
positive responses during the acute stage of the disease. MAXWELL  FINLAND  AND  W.  D.  SUTLIF~F  649 
There were 5 patients with complications in the group tested early 
in convalescence. 
One was a patient, who, 8 days after crisis, showed a positive cutaneous response 
to the Type I  polysaccharide and circulating antibodies for the same type.  On 
the same  day, Type I  pneumococci  were cultured from pus obtained from the 
pleural cavity.  The second patient was afebrile and apparently having a normal 
convalescence on the 9th day after crisis, at which time a positive Type I skin test 
was  obtained and circulating specific antibodies for this type were present.  2 
days later this patient had a rise in temperature, a positive blood culture was ob- 
tained and he died 2 days later.  The organisms  cultured from his blood, as well 
as those cultured at autopsy from the heart's blood, the involved lungs and pleural 
fluid, were Gram-positive,  green-producing  diplococci which were bile insoluble, 
grew in rough colonies and did not agglutinate with any of the specific sera avail- 
able.  This organism may have been a rough pneumococcus.  2 Type I patients 
had sterile pleural effusions; one of these had a positive homologous skin test. 
One other Type I  patient in this group had an empyema; his  skin  tests were 
negative. 
DISCUSSION 
The observations of Tillett and  Francis  (1)  that  the  protein-free, 
type-specific polysaccharide of the homologous pneumococcus elicits 
an immediate  "wheal and erythema" type of reaction when injected 
into  the skin of patients  recovering from pneumococcus lobar pneu- 
monia and that this reaction is associated with the presence of circulat- 
ing specific antibodies has been confirmed.  These authors found posi- 
tive skin reactions in 100 per cent of 21  recovered Type I  cases.  In 
the present  series only one-half of the Type i  and  two-thirds of the 
Type II and Type III cases that recovered showed skin reactions to the 
purified polysaccharide of the pneumococcus causing the disease, but 
these Type I  cases are hardly comparable to those of Tillett and Fran- 
cis, since most of their cases were treatedwith antipneumococcic serum. 
The majority of fatal cases in this series failed to react to the homo- 
logous polysaccharides.  Mention was made above of a  patient who 
gave a  characteristic  skin  response  to  the  Type II  S.S.S.  at  a  time 
when he had  massive blood invasion with Type II pneumococci.  No 
mouse protective antibodies or agglutinins were found in this patient's 
blood serum.  There is no adequate explanation for this peculiar occur- 
rence, but two possibilities may be mentioned.  In the first place, the 
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from the blood stream.  Secondly, this patient may have come in con- 
tact  with  some  substances,  such  as  yeasts  (3),  immunologicaUy 
related to Type II polysaccharide, to which he had become partially 
immunized, and was therefore capable of reacting with the purified 
polysaccharide in the skin. 
In the patients who had repeated skin tests with the specific pneumo- 
coccus polysaccharides antibodies were demonstrated to pneumococci 
heterologous to the type of infecting organism but corresponding to 
the types of polysaccharides used in the skin tests.  Patients tested on 
only one occasion in convalescence did not show he~erologous anti- 
bodies.  Similar observations were recorded by Francis and Tillett (4) 
who suggested that these heterologous antibodies were associated with 
the previous intradermal injections.  Direct experiments with normal 
individuals (5) have shown that the production of type-specific anti- 
bodies may be induced by single or repeated skin test doses of poly- 
saccharides.  It thus seems likely that the type-specific carbohydrates 
injected intradermally in small amounts are antigenic. 
Although heterologous antibodies and sometimes heterologous skin 
tests developed for each of the 3 types in some of the cases, the hetero- 
logous serum antibodies and skin tests were by far most frequent for 
Type II.  The explanation of this fact may depend on the properties 
of the solution of Type II S.S.S. used in this study which was possibly 
more actively antigenic than the Type I and Type III solutions.  On 
the other hand, since  "natural" antibodies for Type II pneumococci 
are present normally in nearlyall adult human bloods (5), the basis for 
more effective immunization to Type II polysaccharide may be present 
in human subjects. 
A study of Fig. 2 will indicate that the skin reaction is a less sensitive 
indicator of antibody production than is either the agglutination or 
mouse protection test.  Furthermore, the large number of negative 
responses in patients who recovered without complications and the 
finding of positive tests in patients with persistent infection indicate 
the disadvantages of the skin test as a prognostic aid.  The agglutina- 
tion test, while demonstrable  somewhat less frequently than mouse pro- 
tection and, thus, a less delicate index of antibody formation, has the 
advantages of simplicity, of the absence of irregularities so often pre- 
sented by the use of the mouse and of rapidity.  When performed by MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  651 
such methods as  those of Arlyle  Noble  (6)  and  of  Sabin  (7),  the 
agglutination reaction is as simple to perform as the skin reaction and 
is less time consuming. 
SUM.MARY  AND  CONCLUSIONS 
1.  A group of 41 non-serum treated patients with Type I, II or III 
pneumococcus  pneumonia  were studied during their disease and conva- 
lescence wiih respect to their skin reactions to specific pneumococcus 
polysaccharides and, in most instances, for the presence of circulating 
agglutinins and protective antibodies for all these 3 types. 
2.  One-half of the Type I  and two-thirds of the Type II and Type 
III recovered cases gave the typical immediate "wheal and erythema" 
response to the homologous polysaccharide at or about the time of 
recovery.  All cases tested showed protective antibodies and almost all 
showed agglutinins for the homologous pneumococcus.  In the fatal 
cases,  in general, positive cutaneous reactions and circulating anti- 
bodies were not obtained. 
3.  In cases of pneumonia receiving repeated cutaneous inoculations 
with various types of specific polysaccharide, antibodies for pneumo- 
cocci differing from the infecting type but corresponding to the types 
of carbohydrate injected were present 1 week or later after such injec- 
tions.  These heterologous antibodies were most  frequently demon- 
strated for Type II and were probably the result of immunization by 
means of the cutaneous injections. 
4.  Positive skin responses to homologous  polysaccharides and corre- 
sponding circulating antibodies were demonstrated with similar fre- 
quency in  the first  3  weeks after  crisis  in  patients who  had  not 
previously received intracutaneous injections.  In such patients het- 
erologous antibodies were rarely found. 
5.  Typical  skin  reactions  with  the  specific  pneumococcus poly- 
saccharides and mouse protective antibodies were demonstrated inde- 
pendently in a  number of hospital patients who had had no recent 
history of pneumonia. 
6.  Some patients with demonstrable foci of persistent infection or 
with latent infections which later proved fatal showed positive cutane- 
ous responses to the homologous type polysaccharide and circulating 
specific antibodies for the corresponding type. 652  REACTIONS AND ANTIBODIES IN  PNEUMONIA.  I 
7.  The agglutination  test, though less sensitive than  the mouse pro- 
tection test for determining the presence of antibody, has many advan- 
tagesover the latter and is simplest to use in following the course of the 
untreated pneumonia. 
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